WallStreetZenWallStreetZen

NYSE: ADCT
Adc Therapeutics Sa Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ADCT

Based on 2 analysts offering 12 month price targets for Adc Therapeutics Sa

Min Forecast
$2.00+81.82%
Avg Forecast
$5.00+354.55%
Max Forecast
$8.00+627.27%

Should I buy or sell ADCT stock?

Based on 2 analysts offering ratings for Adc Therapeutics Sa.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ADCT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ADCT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ADCT stock forecasts and price targets.

ADCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-04
lockedlocked$00.00+00.00%2026-05-05

1 of 1

Forecast return on equity

Is ADCT forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ADCT forecast to generate an efficient return on assets?

Company
N/A
Industry
26.01%

ADCT earnings per share forecast

What is ADCT's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.68
Avg 3 year Forecast
-$0.06

ADCT revenue forecast

What is ADCT's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$82.3M+3.94%
Avg 2 year Forecast
$117.4M+48.22%
Avg 3 year Forecast
$225.6M+184.88%
ADCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADCT revenue growth forecast

How is ADCT forecast to perform vs Biotechnology companies and vs the US market?

Company
39.1%
Industry
33.46%
Market
13.88%
ADCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADCT$1.10$5.00+354.55%Buy
ENTX$2.87$9.00+213.59%Buy
UNCY$5.17$25.33+390.00%Strong Buy
EQ$2.26$10.00+342.48%Strong Buy
NGEN$1.66$12.50+653.01%Buy
View Top Biotech Stocks

Adc Therapeutics Sa Stock Forecast FAQ

Is Adc Therapeutics Sa Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: ADCT) stock is to Buy ADCT stock.

Out of 2 analysts, 0 (0%) are recommending ADCT as a Strong Buy, 1 (50%) are recommending ADCT as a Buy, 1 (50%) are recommending ADCT as a Hold, 0 (0%) are recommending ADCT as a Sell, and 0 (0%) are recommending ADCT as a Strong Sell.

If you're new to stock investing, here's how to buy Adc Therapeutics Sa stock.

What is ADCT's earnings growth forecast for 2026-2028?

(NYSE: ADCT) Adc Therapeutics Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.4%.

Adc Therapeutics Sa's earnings in 2026 is -$136,989,000.On average, 7 Wall Street analysts forecast ADCT's earnings for 2026 to be -$110,529,116, with the lowest ADCT earnings forecast at -$113,429,075, and the highest ADCT earnings forecast at -$104,169,558. On average, 6 Wall Street analysts forecast ADCT's earnings for 2027 to be -$85,955,785, with the lowest ADCT earnings forecast at -$92,239,028, and the highest ADCT earnings forecast at -$76,123,908.

In 2028, ADCT is forecast to generate -$7,135,424 in earnings, with the lowest earnings forecast at -$39,887,147 and the highest earnings forecast at $34,723,186.

What is ADCT's revenue growth forecast for 2026-2028?

(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 39.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.88%.

Adc Therapeutics Sa's revenue in 2026 is $79,175,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $10,467,577,921, with the lowest ADCT revenue forecast at $9,149,114,377, and the highest ADCT revenue forecast at $11,765,563,688. On average, 7 Wall Street analysts forecast ADCT's revenue for 2027 to be $14,925,882,391, with the lowest ADCT revenue forecast at $9,859,604,186, and the highest ADCT revenue forecast at $18,777,230,656.

In 2028, ADCT is forecast to generate $28,687,965,687 in revenue, with the lowest revenue forecast at $10,856,782,865 and the highest revenue forecast at $49,947,967,747.

What is ADCT's forecast return on assets (ROA) for 2026-2029?

(NYSE: ADCT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 26.01%.

What is ADCT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ADCT price target, the average ADCT price target is $5.00, with the highest ADCT stock price forecast at $8.00 and the lowest ADCT stock price forecast at $2.00.

On average, Wall Street analysts predict that Adc Therapeutics Sa's share price could reach $5.00 by Jun 4, 2027. The average Adc Therapeutics Sa stock price prediction forecasts a potential upside of 354.55% from the current ADCT share price of $1.10.

What is ADCT's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: ADCT) Adc Therapeutics Sa's current Earnings Per Share (EPS) is -$0.99. On average, analysts forecast that ADCT's EPS will be -$0.87 for 2026, with the lowest EPS forecast at -$0.89, and the highest EPS forecast at -$0.82. On average, analysts forecast that ADCT's EPS will be -$0.68 for 2027, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at -$0.60. In 2028, ADCT's EPS is forecast to hit -$0.06 (min: -$0.31, max: $0.27).

What is ADCT's forecast return on equity (ROE) for 2026-2029?

(NYSE: ADCT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.